Bridges Investment Management Inc. Has $50.85 Million Position in Stryker Corporation $SYK

Bridges Investment Management Inc. increased its holdings in Stryker Corporation (NYSE:SYK) by 16.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 144,689 shares of the medical technology company’s stock after buying an additional 19,983 shares during the quarter. Bridges Investment Management Inc.’s holdings in Stryker were worth $50,854,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Godfrey Financial Associates Inc. acquired a new position in Stryker in the fourth quarter worth about $26,000. United Financial Planning Group LLC acquired a new position in Stryker in the third quarter worth about $27,000. CGC Financial Services LLC acquired a new position in Stryker in the fourth quarter worth about $29,000. Strive Asset Management LLC acquired a new position in Stryker in the third quarter worth about $30,000. Finally, ANTIPODES PARTNERS Ltd acquired a new position in Stryker in the third quarter worth about $34,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 323,264 shares of company stock valued at $100,659,489 over the last three months. 4.60% of the stock is owned by insiders.

Stryker Trading Down 2.0%

SYK opened at $293.36 on Wednesday. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $112.46 billion, a PE ratio of 33.95, a PEG ratio of 1.89 and a beta of 0.78. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87. The firm has a 50-day moving average price of $321.00 and a two-hundred day moving average price of $347.64.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the previous year, the business posted $2.84 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is 40.74%.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Truist Financial reissued a “hold” rating and issued a $330.00 price target (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Weiss Ratings lowered shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. JPMorgan Chase & Co. dropped their price target on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Jefferies Financial Group reissued a “buy” rating and issued a $465.00 price target on shares of Stryker in a research report on Wednesday, March 4th. Finally, Robert W. Baird set a $385.00 price objective on shares of Stryker in a research note on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $395.48.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.